Template-Based de Novo Design for Type II Kinase Inhibitors and Its Extended Application to Acetylcholinesterase Inhibitors

Abstract

There is a compelling need to discover type II inhibitors targeting the unique DFG-out inactive kinase conformation since they are likely to possess greater potency and selectivity relative to traditional type I inhibitors. Using a known inhibitor, such as a currently available and approved drug or inhibitor, as a template to design new drugs via computational de novo design is helpful when working with known ligand-receptor interactions. This study proposes a new template-based de novo design protocol to discover new inhibitors that preserve and also optimize the binding interactions of the type II kinase template. First, sorafenib (Nexavar ® ) and nilotinib (Tasigna ® ), two type II inhibitors with different ligand-receptor interactions, were selected as the template compounds. The five-step protocol can reassemble each drug from a large fragment library. Our procedure demonstrates that the selected template compounds can be successfully reassembled while the key ligand-receptor interactions are preserved. Furthermore, to demonstrate that the algorithm is able to construct more potent compounds, we considered kinase inhibitors and other protein dataset, acetylcholinesterase (AChE) inhibitors. The de novo optimization was initiated using a template compound possessing a less than optimal activity from a OPEN ACCESSMolecules 2013, 18 13488 series of aminoisoquinoline and TAK-285 inhibiting type II kinases, and E2020 derivatives inhibiting AChE respectively. Three compounds with greater potency than the template compound were discovered that were also included in the original congeneric series. This template-based lead optimization protocol with the fragment library can help to design compounds with preferred binding interactions of known inhibitors automatically and further optimize the compounds in the binding pockets.

Hypothalamic and ovarian transcriptome profiling reveals potential candidate genes in low and high egg production of white Muscovy ducks (Cairina moschata)

“…The molecular functions in the ovary revealed that the highest DEGs were recorded in “transferase phosphorus containing group” followed by “phosphotransferase activity alcohol group as acceptor.” It has been reported that transferase are highly essential in a wide range of physiological activities by catalyzing different biological processes that are important to a living system ( Fyte et al, 2012 ). Moreover, phosphotransferase, also known as phosphorus transferases is a large enzyme category among all transferases ( Su et al, 2013 ). The activities of transferase include but are not limited to essential metabolism, genetic regulations, and detoxification ( Fyte et al, 2012 ).…”

MoleGear: A Java-Based Platform for Evolutionary De Novo Molecular Design

“…Computational chemistry plays an important role in the design of new drug-like molecules [1,2,3,4,5], catalysts [6,7,8], and novel solvents of ionic liquids [9,10,11]. De novo molecular design has been an active research area of drug design/discovery over the last decades, and many approaches such as LUDI [12], LEA3D [13], Flux [14,15], and pharmacophore-linked fragment virtual screening (PFVS) [16] have been developed by using protein and ligand structures.…”